novo nordisk glp-1 receptor agonist weight management diabetes treatments The Landscape Of Agonists In And Obesity Treatment Novo, Lilly weight-loss drugs should

Future applications of GLP-1-RA may extend beyond current differentiation strategies, potentially enabling targeted tissue-specific modulation through biomaterial integration, gene editing, or combination therapies

MI and Stroke both contribute to 75% of death in type 2 diabetic patients

Leipold G, Tth R, Hrsfalvi P, Lczi L, Trk M, Keszthelyi A, et al

[112] found a decrease in LFC in patients with moderate to severe NAFLD with T2DM using exenatide in combination with dapagliflozin

Results While GLP-1 and GIP agonists demonstrate significant metabolic benefits, their long-term use is often limited by gastrointestinal side effects and psychological impacts